Blueshift Asset Management’s Regenxbio RGNX Stock Holding History

Blueshift Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,104	Closed	-$402K	–	957
2022 Q1	$402K	Buy	+12,104	New	+$336K	0.04%	507
2021 Q3	–	Sell	-11,342	Closed	-$441K	–	1256
2021 Q2	$441K	Buy	+11,342	New	+$406K	0.02%	603
2019 Q1	–	Sell	-7,642	Closed	-$321K	–	893
2018 Q4	$321K	Buy	+7,642	New	+$448K	0.06%	471

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Blueshift Asset Management's RGNX Position: Q2 2022 in Review

Blueshift Asset Management sold out of Regenxbio (RGNX) in Q2 2022, closing a stake of 12,104 shares — an estimated $402K sold.

Blueshift Asset Management first reported a position in RGNX in Q4 2018 and held it in 3 quarters. The position peaked at $441K in Q2 2021. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2022.

Blueshift Asset Management reported no remaining Regenxbio position as of Q2 2022 after selling out during the quarter.
Blueshift Asset Management sold 12,104 Regenxbio shares in Q2 2022, an estimated $402K.
Blueshift Asset Management first reported a position in Regenxbio in Q4 2018 and held it in 3 quarters.
Blueshift Asset Management's Regenxbio position peaked at $441K in Q2 2021.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.